Stay updated on Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial

Sign up to get notified when there's something new on the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    1.0%
    Check dated 2025-07-04T04:10:21.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.8%
    Check dated 2025-06-19T20:07:35.000Z thumbnail image
  4. Check
    23 days ago
    No Change Detected
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:26:49.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T06:13:42.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T18:02:44.000Z thumbnail image
  8. Check
    80 days ago
    Change Detected
    Summary
    The page has undergone significant changes, including the removal of detailed descriptions of a Phase 2 study for poziotinib in NSCLC, which included participant cohorts and eligibility criteria. Additionally, a new revision number has been added, indicating an update to the document.
    Difference
    29%
    Check dated 2025-04-16T12:44:12.000Z thumbnail image

Stay in the know with updates to Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page.